News
Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I reiterate buy rating on NVO stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback